Harlan M. Mellk, M.D.; Joseph M. Letteri, M.D., F.A.C.P.; Peter Durante, M.D.; Sidney Louis, M.D.; Henn Kutt, M.D.; Anthony Glazko, Ph.D.
This content is PDF only. Please click on the PDF icon to access.
The metabolic fate of diphenylhydantoin, a commonly used anticonvulsant in uremia, is not known. Studies were performed in adult uremic patients with a mean plasma creatinine of 12.6 ± 5 mg/100 ml (range, 5.5 to 22 mg/100 ml). These patients did not receive peritoneal or extracorporeal dialysis during the study. Ten patients received 300 mg of oral diphenylhydantoin daily for 28 days. Mean diphenylhydantoin plasma concentrations at 28 days was 4.7 ± 1.8 μg/ml. In nonuremic individuals equivalent dosage schedules produced concentration of 9.5 ± 4.4 μg/ml, a difference which is highly significant (P < 0.01). Five patients received 400
Mellk HM, Letteri JM, Durante P, et al. Diphenylhydantoin Metabolism in Chronic Uremia.. Ann Intern Med. 1970;72:801. doi: https://doi.org/10.7326/0003-4819-72-5-801_3
Download citation file:
Published: Ann Intern Med. 1970;72(5):801.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use